Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Issued (2016 - 2025)

Altimmune (ALT) has disclosed Shares Issued for 16 consecutive years, with $111.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 60396.22% to $111.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $112.0 million, a 691.98% increase, with the full-year FY2024 number at $300000.0, up 39.53% from a year prior.
  • Shares Issued was $111.9 million for Q3 2025 at Altimmune, up from $166000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $121.0 million in Q4 2022 to a low of -$52.3 million in Q3 2021.
  • A 5-year average of $14.6 million and a median of $166000.0 in 2025 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: plummeted 386.21% in 2021, then soared 96700.0% in 2022.
  • Altimmune's Shares Issued stood at $125000.0 in 2021, then skyrocketed by 96700.0% to $121.0 million in 2022, then plummeted by 88.59% to $13.8 million in 2023, then plummeted by 100.33% to -$46000.0 in 2024, then skyrocketed by 243400.0% to $111.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Shares Issued are $111.9 million (Q3 2025), $166000.0 (Q2 2025), and $4000.0 (Q1 2025).